Sept 7 (Reuters) - Sigma Healthcare Ltd SIG.AX :
* Sales revenue heavily impacted this year by pull back in sales of low margin hepatitis C medicines, exit of non-compliant branded customer group
* Confirms trading update provided on 11 August 2017 guiding to expected underlying EBIT of $90 million for FY2018
* A number of factors point to a more positive outlook for FY2019